Browse by author
Lookup NU author(s): Dr Penelope Taylor, Dr Kevin Windebank, Dr Helen Lucraft, Dr Katrina Wood, Dr Brian Angus, Professor Stephen Proctor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The aim was to assess outcome in a population-based cohort of adolescents with Hodgkin's lymphoma (HL) diagnosed in the UK's northern region over a 10-year period. Among a population of 3.09 million, 55 of 676 patients (8%) diagnosed with HL were aged 13-19. Seven had nodular lymphocyte-predominant HL, 48 classical HL (cHL). Of the latter, 36 were ≥16 years. Application of the Scottish and Newcastle Lymphoma Group (SNLG) prognostic index meant 21 patients were considered high risk (index ≥0.5). They received PVACEBOP multi-agent chemotherapy as primary therapy. Standard risk patients (SNLG index <0.5) were treated with standard ChlVPP or ABVD chemotherapy±radiotherapy. Scottish and Newcastle Lymphoma Group indexing is not valid for patients under 16. Twelve patients therefore received UKCCSG protocols (n=8), ABVD plus radiotherapy (n=2), or PVACEBOP (n=2). Forty-six patients with cHL (96%) achieved complete remission. Seven patients relapsed but all entered complete remission after salvage therapy. Five patients died: three of HL, one in an accident and one of disseminated varicella complicating cystic fibrosis. Five- and 10-year overall survival was 93 and 86%, respectively; disease-specific survival was 95 and 92%. The data suggest that older adolescents with high-risk HL require intensive protocols as primary therapy to secure optimal outcome. © 2007 Cancer Research UK.
Author(s): Jones GL, Taylor PRA, Windebank KP, Hoye NA, Lucraft HH, Wood K, Angus B, Proctor SJ
Publication type: Article
Publication status: Published
Journal: British Journal of Cancer
Year: 2007
Volume: 97
Issue: 1
Pages: 29-36
Print publication date: 26/06/2007
ISSN (print): 0007-0920
ISSN (electronic): 1532-1827
URL: http://dx.doi.org/10.1038/sj.bjc.6603809
DOI: 10.1038/sj.bjc.6603809
PubMed id: 17533403
Altmetrics provided by Altmetric